The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
|9/2/2019||135,000 Orion Corporation A shares converted into B shares|
|7/17/2019||Orion Group Half-Year Financial Report January–June 2019|
|7/17/2019||Orion Corporation's financial reporting and Annual General Meeting in 2020|
|6/19/2019||1,767 Orion Corporation A shares converted into B shares|
|9/10/2019||Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers|
|8/7/2019||Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone|
|7/31/2019||U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)|
|7/15/2019||Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.